Perspectives on contraceptive implant use in women living with HIV in Cape Town, South Africa: a qualitative study among primary healthcare providers and stakeholders.
Antiretroviral therapy
Contraceptive implants
HIV
LARCs
Long-acting reversible contraceptives
Qualitative
South Africa
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
26 Jul 2019
26 Jul 2019
Historique:
received:
27
09
2018
accepted:
12
07
2019
entrez:
28
7
2019
pubmed:
28
7
2019
medline:
28
10
2019
Statut:
epublish
Résumé
This study explored primary healthcare provider and HIV/contraception expert stakeholder perspectives on South Africa's public sector provision of contraceptive implants to women living with HIV. We investigated the contraceptive service-impact of official advice against provision of implants to women using the HIV antiretroviral drug, efavirenz, issued by the South African National Department of Health (NDoH) in 2014. Qualitative data was collected in Cape Town in 2017 from primary healthcare contraceptive providers in four clinics that provide implants, as well as from other expert stakeholders selected for expertise in HIV and/or contraception. In-depth interviews and a group discussion explored South Africa's implant introduction and implant provision to women living with HIV. Data was analysed using an inductive thematic analysis approach. Interviews were conducted with 10 providers and 10 stakeholders. None of the four clinics where the providers worked currently offered the implant to women living with HIV. Stakeholders confirmed that this was consistent with patterns of implant provision at primary healthcare facilities across Cape Town. Factors contributing to providers' decisions to suspend provision of the implant to women living with HIV included: inadequate initial and ongoing provider training; interpretation of NDoH communications about implant use with efavirenz; provider unwillingness to risk harming clients and concerns about professional liability; and other pressures related to provider capacity. All South African women, including those living with HIV, should have access to the full range of contraceptive options for which they are medically eligible. Changing guidance should be initiated and communicated in consultation with primary-level providers and service beneficiaries. Guidance issued to providers needs to be clear and fully evidence-informed, and its correct interpretation and implementation facilitated and monitored. Guidance should be accompanied by provider training, as well as counselling messages and tools to support providers. Generalized retraining of providers in rights-based, client-centred family planning, and in particular implant provision for women with HIV, is needed. These recommendations accord with the right of women living with HIV to access the highest possible standard of sexual and reproductive healthcare, including informed contraceptive choice and access to the contraceptive implant.
Sections du résumé
BACKGROUND
BACKGROUND
This study explored primary healthcare provider and HIV/contraception expert stakeholder perspectives on South Africa's public sector provision of contraceptive implants to women living with HIV. We investigated the contraceptive service-impact of official advice against provision of implants to women using the HIV antiretroviral drug, efavirenz, issued by the South African National Department of Health (NDoH) in 2014.
METHODS
METHODS
Qualitative data was collected in Cape Town in 2017 from primary healthcare contraceptive providers in four clinics that provide implants, as well as from other expert stakeholders selected for expertise in HIV and/or contraception. In-depth interviews and a group discussion explored South Africa's implant introduction and implant provision to women living with HIV. Data was analysed using an inductive thematic analysis approach.
RESULTS
RESULTS
Interviews were conducted with 10 providers and 10 stakeholders. None of the four clinics where the providers worked currently offered the implant to women living with HIV. Stakeholders confirmed that this was consistent with patterns of implant provision at primary healthcare facilities across Cape Town. Factors contributing to providers' decisions to suspend provision of the implant to women living with HIV included: inadequate initial and ongoing provider training; interpretation of NDoH communications about implant use with efavirenz; provider unwillingness to risk harming clients and concerns about professional liability; and other pressures related to provider capacity.
CONCLUSIONS
CONCLUSIONS
All South African women, including those living with HIV, should have access to the full range of contraceptive options for which they are medically eligible. Changing guidance should be initiated and communicated in consultation with primary-level providers and service beneficiaries. Guidance issued to providers needs to be clear and fully evidence-informed, and its correct interpretation and implementation facilitated and monitored. Guidance should be accompanied by provider training, as well as counselling messages and tools to support providers. Generalized retraining of providers in rights-based, client-centred family planning, and in particular implant provision for women with HIV, is needed. These recommendations accord with the right of women living with HIV to access the highest possible standard of sexual and reproductive healthcare, including informed contraceptive choice and access to the contraceptive implant.
Identifiants
pubmed: 31349786
doi: 10.1186/s12889-019-7312-1
pii: 10.1186/s12889-019-7312-1
pmc: PMC6660962
doi:
Substances chimiques
Alkynes
0
Benzoxazines
0
Contraceptive Agents, Female
0
Cyclopropanes
0
Drug Implants
0
efavirenz
JE6H2O27P8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1003Subventions
Organisme : Joint Cape Higher Education Consortium- Western Cape Government Grant (ZA)
ID : Awarded to the School of Public Health at University of the Western Cape and the School of Public Health and Family Medicine at University of Cape Town
Références
Sex Transm Dis. 2006 Jun;33(6):350-6
pubmed: 16505747
Bull World Health Organ. 2009 Nov;87(11):833-9
pubmed: 20072768
Obstet Gynecol. 2011 Mar;117(3):705-19
pubmed: 21343774
Stud Fam Plann. 2010 Dec;41(4):241-50
pubmed: 21465725
AIDS. 2014 Mar 13;28(5):791-3
pubmed: 24401645
J Acquir Immune Defic Syndr. 2014 Aug 1;66(4):378-85
pubmed: 24798768
Glob Health Sci Pract. 2013 Mar 21;1(1):11-7
pubmed: 25276512
Glob Health Sci Pract. 2013 Jul 26;1(2):203-12
pubmed: 25276533
Lancet HIV. 2015 Nov;2(11):e454-5
pubmed: 26520921
Lancet HIV. 2015 Nov;2(11):e474-82
pubmed: 26520927
AIDS. 2015 Nov;29(17):2353-9
pubmed: 26544706
J Int AIDS Soc. 2017 May 11;20(1):21396
pubmed: 28530033
S Afr Med J. 2017 Oct 01;107(10):815-821
pubmed: 29397680
S Afr Med J. 2017 Oct 01;107(10):822-826
pubmed: 29397681
S Afr Med J. 2017 Oct 01;107(11):933-938
pubmed: 29399422
S Afr Med J. 2017 Nov 01;107(11):939-944
pubmed: 29400025